BB Biotech (BION)

Last close As at 22/06/2024

CHF38.80

0.10 (0.26%)

Market capitalisation

CHF2,150m

BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but is managed on a bottom-up basis, with a focused c 20–35 stock portfolio.

Latest Insights

View More

Investment Companies | Review

BB Biotech — A recovering sector with a healthy prognosis

Investment Companies | Update

BB Biotech — A cutting-edge sector and a high dividend

Investment Companies | Update

BB Biotech — Picking growth at good value

Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

Equity Analyst

Joanne Collins

Joanne Collins

Analyst, Investment Trusts

Key Management

  • Claude Mikkelsen

    Director of IR

  • Daniel Koller

    Head of investment management

  • Dr Silvia Siegfried-Schanz

    Director of IR

  • Erich Hunziker

    Chairman

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (7.0) (18.7) (7.9)
Relative (7.6) (22.2) (14.9)
52 week high/low CHF49.4/CHF35.6

Overview

BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opportunities. BION’s performance has picked up in recent months, supported by an improvement in the market environment. Its managers are optimistic about the outlook as declines in interest rates, whenever they eventuate, begin to boost investor sentiment towards the sector, especially the mid- and small-cap companies that BION favours. The fund’s managers also expect ongoing progress by portfolio holdings, as several reach key milestones over the coming months. Unlike most of its peers, BION pays an attractive 5% dividend, calculated on average share price over December each year.

Research

Review

Investment Companies

BB Biotech — High-conviction specialist with impressive record

Review

Investment Companies

BB Biotech — Update 27 February 2017

edison tv

Investment Companies

Bitesize Briefings – BB Biotech

Review

Investment Companies

BB Biotech AG — Update 8 February 2016

thematic

Investment Companies

European equities

thematic

Investment Companies

Listed Private Equity

thematic

Investment Companies

Vietnamese equities: Due a comeback?

thematic

Investment Companies

Investment companies: Latin America is worthy of consideration

thematic

Consumer

IPO apocalypse

thematic

TMT

ESG, moving beyond the box tick

thematic

Investment Companies

The case for US capital markets

thematic

Investment Companies

Value Investing: Living with the reality, waiting for the inevitable

thematic

Consumer

Illuminator: August Update

thematic

Investment Companies

Post Woodford- A spotlight on smaller company liquidity

thematic

Investment Companies

How to buy and sell investment trusts

thematic

Investment Companies

Types of investment trusts

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Investment Companies

Investment Trusts Quarterly: Biotechnology & healthcare trusts

thematic

Investment Companies

Investment Trusts Quarterly: Growth and income